Thursday, 15 November 2018

MGI brings innovative genetic sequencer, MGISEQ-T7

29 October 2018 | News

The MGI proprietary technology used in T7 delivers higher accuracy and improves efficiency through upgrades to the flow cell, fluid, and biochemical and optical system.

MGI, a subsidiary of BGI Group, introduced its newest model of genetic sequencer, MGISEQ-T7, which vastly improves speed, throughput and flexibility, at the 13th International Conference on Genomics (ICG-13) in Shenzhen.

The most powerful MGI sequencer to date, MGISEQ-T7 is built with innovative quadruple flow-cell staging that allows simultaneous but independent operation of 1 to 4 flow cells in a single run.

The MGI proprietary technology used in T7 delivers higher accuracy and improves efficiency through upgrades to the flow cell, fluid, and biochemical and optical system. A supercomputer for the life science industry, MGISEQ-T7 takes the production capacity of the sequencer to a new level with the daily output of data up to 6Tb.

"Now customers have complete flexibility for a wide range of sequencing all in one machine," said MGI CEO Feng Mu.

"MGI is the first company that can achieve affordable and essentially error-free genome sequencing," said Dr. George Church, Professor of Genetics, and Health Sciences and Technology of Harvard and MIT.

The ultra-fast, ultra-high-throughput MGISEQ-T7 can complete WGS for up to 60 human genomes in a single day, breaking barriers for what a next-generation sequencer can do. MGISEQ-T7 accelerates the development of nationwide genomics projects since a T7 can complete the sequencing of 10,000 genomes within a year.

BGI Group President Jian Wang said such research will benefit human beings everywhere. "The mission of MGI is to help people live better and healthier lives."

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Are New-Age Healthcare Consumers In Asia Embracing Technology?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls